The participations - sustainable

Here is a description of the purposes for which the companies use your shares.

Science for Life - that is what we support with our partnerships.

BiotechProfSchleuning invests in biotech companies in the USA with a focus on new immunotherapies/oncology. The companies have a market capitalization that is roughly between $50 million and $900 million. We focus on companies that have one or more drugs/preparations/applications in Phase 3 clinical trials. For our companies, we strive to have direct, personal contact with (a) scientific leadership and (b) CEOs.

We participate in companies that convince us mainly by their scientific approach and a top-class scientific team. Thus, one or the other Nobel Prize winner can be found in the companies. The companies should achieve significant development steps – from the time of the investment – within 9 to 20 months. The companies are traded on the markets of NYSE, AMEX, NASDAQ or via OTC exchanges. We aim – in addition to these trading venues – for direct company investments.

PolyPid: Strong Pipeline, Close Catalysts

Here you can find a publication about one of our investments, the company PolyPid, written by Nils Decrop and Dr. Kai Blau. >> Link Seeking Alpha.
(The link leads to the website Seeking Alpha, one of the largest and best known investor websites. The article can only be read with a Seeking Alpha account, which can be created for free. It is possible to deny all cookies of the website without any restrictions).

An insight - four examples

Company Protein

Proprietary protein therapeutics with clinically improved profiles – that’s what this company is all about. Their product portfolio includes a therapeutic protein candidate in Phase III clinical trials for the treatment of Fabry disease.

The company is focused on recombinant therapeutic proteins produced by a proprietary protein expression system based on plant cells. Potentially clinically superior versions of recombinant therapeutic proteins targeting established pharmaceutical markets are currently under development. These include a proprietary recombinant form of human deoxyribonuclease I from plant cells for the treatment of cystic fibrosis and a recombinant PEGylated uricase expressed in plant cells for the treatment of gout. Company Protein can develop and commercialize recombinant proteins without infringing on the method-based patents or other intellectual property rights of third parties. The system used has lower scale-up (CapEx) and production costs, and can develop therapeutic proteins for clinical trials faster than other platforms. Thus Company Protein has a unique technology platform and in-house research and development capabilities.

Company protein has already received FDA approval for one product, another is in Phase III clinical trials, and other products are in Phase IIa.

Company Cell Therapy

Company Cell Therapy focuses on the development and commercialization of bone marrow transplant (BMT) therapies and other adaptive cell therapies. Its lead candidate product is in a pivotal Phase III clinical trial for elderly people with relapsed or refractory acute myeloid leukemia for BMT conditioning.

The Company Cell Therapy develops focused radiation therapies based on its own technology platform. The company is currently researching a clinical-stage, multi-disease, multi-target pipeline of antibody-radiation conjugates that can be used for targeted conditioning and as therapeutic agents. The conjugates can potentially be used either in combination with other therapeutic modalities (in collaboration with other companies) or as a single agent for patients with hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. The conjugates offer highly effective and selective forms of radiation therapy that enable precise targeting of their proven therapeutic power to tumors and synergistic potential with other therapeutic modalities that cannot be achieved with conventional external beam radiation, cytotoxic chemotherapy or biological therapies. Through its technology platform, the company aims to use multiple radioisotopes to meet the specific requirements of the desired indication.

The company is a leader in using a potent alpha-emitting radioisotope and has demonstrated the ability to isotopically target both hematologic and solid tumors.

Company Plasma

The company’s lead product candidate is in Phase 3 clinical trials for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.

This company’s new drug development approach is based on the use of a proprietary controlled release technology that improves the way drugs are dosed and released.

The current drug is a once-per-night extended-release formulation. The once-per-night drug may be safer due to consequences associated with the dosing regimen of the previously approved twice-per-night product.

Company Fusion Protein Therapeutics

Company Fusion Protein Therapeutics focuses on the development and commercialization of targeted fusion protein therapeutics (TFPTs) for the treatment of cancer patients.

The company’s lead product candidates include a locally administered targeted fusion protein that is in Phase III clinical trials for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) and a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors.

While BCG is effective in many patients, challenges with tolerability have been observed and many patients experience disease recurrence. When BCG is not effective or a patient can no longer receive BCG, the recommended treatment option is radical cystectomy, the complete removal of the bladder.

Criteria for analysis

More than 100 criteria are included in the algorithm we developed to evaluate the companies.

 

Here is a small excerpt.

The excerpt shown is again only an extract, behind which stand individual analyses by our science team as well as third scientists.

 

If you have any further questions, please feel free to contact us.